Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Polaryx TherapeuticsPLYX -1.44%13 3-1 Month Momentum % is -34.75% as of Aug. 29, 2026. GuruFocus rates PLYX with a GF Score™ of 13/100. Among 1,389 Biotechnology companies, Polaryx Therapeutics ranks worse than 73.36% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-29), Polaryx Therapeutics's 3-1 Month Momentum % is -34.75%.
The industry rank for Polaryx Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
PLYX's 3-1 Month Momentum % is ranked worse than 73.36% of 1389
companies
in the Biotechnology industry
Industry Median: -8
vs PLYX: -34.75
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Polaryx Therapeutics 3-1 Month Momentum % Related Terms
PLYX vs BDTX, ENTX, ICCC: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Polaryx Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polaryx Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Polaryx Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Polaryx Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polaryx Therapeutics (PLYX) has a 3-1 Month Momentum % of -34.75% as of Aug. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Polaryx Therapeutics and its competitors. According to the industry distribution chart, Polaryx Therapeutics ranks #1019 out of 1389 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Polaryx Therapeutics' 3-1 Month Momentum % too high?
Polaryx Therapeutics' current 3-1 Month Momentum % is -34.75%. Based on the distribution chart, Polaryx Therapeutics ranks #1019 out of 1389 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' 3-1 Month Momentum % compare to BDTX and ENTX?
According to the Biotechnology industry distribution chart, Polaryx Therapeutics ranks #1019 out of 1389 companies for 3-1 Month Momentum %. This places Polaryx Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current 3-1 Month Momentum % is -34.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current 3-1 Month Momentum % of -34.75%. The current 3-1 Month Momentum % is -34.75%. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current 3-1 Month Momentum % is -34.75% as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score
Get the complete analysis for PLYX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYX has been successfully added to your 
